Welcome to our 61st episode and the beginning of our sixth season! Join host Chase Hendrickson, MD, from Vanderbilt University Medical Center, in a discussion about a recently published clinical trial in The Journal of Clinical Endocrinology & Metabolism that tries to understand the impact of genetics on the benefits of a lifestyle program in reducing the risk of developing type 2 diabetes. Personalized or precision medicine has been a hot topic for several years now, and this podcast has recently reviewed a few studies that fit that description. The authors of this investigation try to answer the question of how we can decide in advance which patients are particularly likely to benefit from a given intervention. Dr. Hendrickson talks with Ashok Balasubramanyam, MD, from Baylor College of Medicine, and guest expert Miriam Udler, MD, PhD, from Massachusetts General Hospital. The article featured this month, by Lankinen et al, was published in the January 2025 issue of JCEM: “Effects of Genetic Risk on Incident Type 2 Diabetes and Glycemia: The T2D-GENE Lifestyle Intervention Trial.” Show notes can be found at https://www.endocrine.org/journals/endocrine-feedback-loop-podcast-series/efl061 — podcast home page: https://www.endocrine.org/journals/endocrine-feedback-loop-podcast-series

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related